medicines
-
22-Feb-2019 USA Today
How drug prices could derail new trade pact to replace NAFTA
Democrats in Congress contend that the new pact would force Americans to pay more for prescription drugs, and their argument has dimmed the outlook for one of Trump’s signature causes.
-
18-Feb-2019 VOA Noticias
Precios de las medicinas podrían amenazar el nuevo TLCAN
Dicen que el acuerdo hará que los estadounidenses paguen más por dichos productos.
-
8-Feb-2019 The Star
Provision that could raise drug costs emerges as key obstacle to NAFTA approval
Some Democrats in the US, like Canada’s generic drug industry, warn that the new biologics rule would keep drug prices high by requiring citizens to wait longer before they can get their hands on lower-cost similar drugs known as biosimilars.
-
25-Jan-2019 Chile Mejor sin TLC
Chile: Fundación Equidad alerta que el TPP-11 afectará el ingreso de genéricos al país y pide discusión en la Comisión de Salud
Luego de que el polémico Tratado Integral y Progresista de Asociación Transpacífico, más conocido como TPP-11, fuese aprobado este miércoles en la Comisión de Relaciones Exteriores, la Fundación Equidad Chile emplazó a los diputados de la Comisión de Salud que lo analicen antes de que pase a votación en sala.
-
23-Jan-2019 Mapuexpress
Organizaciones del Wallmapu dicen ¡No al TPP!
"Decimos ¡NO AL TPP!, por nuestra salud, por nuestra soberanía como pueblos, por la protección del medio ambiente, por la protección del conocimiento ancestral mapuche, por la protección de los derechos de las trabajadoras y trabajadores, por nuestra soberanía alimentaria, rechazamos enérgicamente este tratado, e instamos a las parlamentarias y parlamentarios, en especial de la región de La Araucanía, a rechazar este tratado".
-
22-Jan-2019 Public Citizen
More than 70 US health, consumer and other groups demand elimination of NAFTA 2.0 terms that would lock in high US medicine prices
In a letter to Congress, the groups demand that the pact’s giveaways to Big Pharma that would keep medicines unaffordable be removed before the pact is sent to Congress.
-
17-Jan-2019 Diario Uchile
“Gol a Chile”: Gobierno presiona y Comisión de Relaciones Exteriores aprueba el TPP-11
Al día siguiente que se pusiera suma urgencia para la aprobación del Tratado Integral y Progresista de Asociación Transpacífico, el acuerdo pasará a ser debatido en la Comisión de Hacienda.
-
17-Jan-2019 Chile Mejor sin TLC
TPP-11: Votación con suma urgencia viola todo principio democrático e impide su análisis en profundidad
Chile | Este 16 de enero la Comisión de Relaciones Exteriores de la Cámara de Diputados aprobó el Tratado de Asociación transpacífico con 10 votos a favor, 2 en contra y una abstención.
-
14-Jan-2019 Chicago Tribune
We can’t afford to let the new NAFTA drive up drug prices
NAFTA 2.0 would effectively tie the US Congress’ hands in the struggle against rising drug prices.
-
12-Dec-2018 PhRMA
Comments on negotiating objectives for a US-Japan trade agreement
US drug manufacturers want Japan to provide 12 years of data protection for biologic medicine in upcoming trade talks. That would be four more years than Japan currently provides.
-
12-Dec-2018 Public Citizen
TLCAN 2.0: Acuerdo Estados Unidos-México-Canadá. Capítulo 20: disposiciones de patentes relacionadas con productos farmacéuticos
El capítulo de propiedad intelectual del TLCAN 2.0 incluye disposiciones que amenazan y debilitan laposibilidad de conseguir una adecuada atención en salud y medicamentos asequibles.
-
5-Dec-2018 Public Citizen
NAFTA 2.0: US-Mexico-Canada Agreement. Chapter 20: pharmaceutical related patent provisions
The Intellectual Property Chapter of the revised NAFTA, rebranded by the Trump Administration USMCA, includes provisions that threaten to undermine critical efforts towards affordable health care and medicine.
-
26-Nov-2018 The Diplomat
Indonesia and RCEP: Beware the public health risks
Proposals from Japan and South Korea would require patent law changes in several RCEP countries, including Indonesia.
-
19-Nov-2018 Peoples Dispatch
PHA4: Neoliberal policies and corporate takeover are the cause of the world health crisis
Multinational corporations are suing countries for using generic versions of life saving medicines.
-
12-Nov-2018 Public Eye
Switzerland should stop pushing for TRIPS-plus measures in trade agreement with Indonesia
Swiss and Norwegians civil society groups addressed their serious concerns over TRIPS-plus provisions being included in the trade agreement under negotiation between the European Free Trade Association (EFTA) and Indonesia.
-
12-Nov-2018 Don’t trade our lives away
RCEP and affordable medicines: Civil society reaches out to Minister of Commerce Suresh Prabhu
Civil society organisations, patient groups and health activists have been concerned about intellectual property provisions being discussed in RCEP which undermine access to medicines and affordable treatment for patients
-
8-Nov-2018 IGJ
Indonesia-EFTA CEPA TRIPS-plus, threat for access to medicines and the right to health of millions of people in Indonesia
In many countries, the implementation of the TRIPS-plus measures has significantly increased the cost of medicines.
-
8-Nov-2018 The Guardian.pe.ca
Drugs costs impact health
Canada’s negotiators extended data protection on biologics without knowing impact on prices.
-
9-Oct-2018 European Pharmaceutical Manufacturer
Trade and patent changes could increase healthcare costs by $100bn, CPHI annual report warns
Patients may need to wait an extra five or 10 years to access generic medicines, which could raise healthcare costs by as $100 billion over the next five years, according to the latest CPhI annual report
-
5-Oct-2018 Financial Post
Canada ’caved’ on intellectual property provisions in USMCA trade deal, experts say
Experts are fuming, saying USMCA will hamper Canada’s innovation economy and hike costs to the health care system over patented drugs.
